Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astellas Pharma Unsp/Adr (ALPMY)

Astellas Pharma Unsp/Adr (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Astellas Pharma Unsp/Adr 2-5-1 Nihonbashi-Honcho Chuo-Ku Tokyo M0 103-8411 JPN

www.astellas.com P: 813-3244-3000

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.

Key Statistics

Overview:

Market Capitalization, $K 29,298,398
Enterprise Value, $K 33,542,548
Shares Outstanding, K 1,809,660
Float, K 1,809,660
% Float 100.00%
Short Interest, K 46
Short Float 0.00%
Days to Cover 1.00
Short Volume Ratio 0.46
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 12,621 M
Annual Net Income, $ 334,930 K
Last Quarter Sales, $ 3,708 M
Last Quarter Net Income, $ 651,300 K
EBIT, $ 996,200 K
EBITDA, $ 2,488 M

Growth:

1-Year Return 68.82%
3-Year Return 16.31%
5-Year Return 2.05%
5-Year Revenue Growth 5.76%
5-Year Earnings Growth 13.54%
5-Year Dividend Growth 17.24%

Per-Share Information:

Most Recent Earnings 0.30 on 10/30/25
Next Earnings Date 04/24/26
Earnings Per Share ttm 1.41
EPS Growth vs. Prev Qtr 46.67%
EPS Growth vs. Prev Year 46.67%
Annual Dividend & Yield (Paid) 0.34 (2.12%)
Annual Dividend & Yield (Fwd) 0.34 (2.10%)
Most Recent Dividend 0.170 on 09/26/25
Next Ex-Dividends Date 09/26/25
Dividend Payable Date 12/18/14
Dividend Payout Ratio 12.50%
Most Recent Split 5-4 on 04/02/14

ALPMY Ratios

Ratio
Price/Earnings ttm 11.49
Price/Earnings forward 25.51
Price/Earnings to Growth N/A
Return-on-Equity % 23.62%
Return-on-Assets % 10.96%
Profit Margin % 2.65%
Debt/Equity 0.46
Price/Sales 2.13
Price/Cash Flow 9.00
Price/Book 2.94
Book Value/Share 0.00
Interest Coverage 2.77
60-Month Beta 0.18

ALPMY Dividends

Date Value
09/26/25 $0.1700
03/27/25 $0.1740
09/28/24 $0.1670
03/26/24 $0.1520
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar